everolimus / Generic mfg. 
Welcome,         Profile    Billing    Logout  
 471 Diseases   207 Trials   207 Trials   10577 News 


«12...5152535455565758596061...132133»
  • ||||||||||  Prolia (denosumab) / Amgen, Daiichi Sankyo, Cabometyx (cabozantinib tablet) / Takeda, Exelixis, Ipsen
    [VIRTUAL] Are Multiple Brands Used to Charge Higher Prices for Orphan Drug Designations in the US? () -  Apr 12, 2021 - Abstract #ISPOR2021ISPOR_257;    
    For one month of treatment, the ratios of prices between orphan and non-orphan indications were: 11.163 for denosumab, 7.724 for everolimus, 2.707 for hydroxyurea, 2.683 for peginterferon alfa-2b, 1.062 for cabozantinib, and 0.930 for tolvaptan (ratios >1 indicate higher cost for the orphan indication)...CONCLUSIONS While certain drugs are significantly more expensive when used in an orphan indication, others do not follow this same pattern. Further research is needed to explore additional drug databases in the US and other countries.
  • ||||||||||  everolimus / Generic mfg.
    [VIRTUAL] Real-world experience of mTOR inhibitors in liver transplant recipients in a region where living donation is predominant (Poster area) -  Apr 9, 2021 - Abstract #EASLILC2021EASL_ILC_638;    
    Overall, this is the first real-world report of mTOR inhibitor application in Korea, where hepatitis B virus (HBV) infection is the principal cause of HCC and living donor LT is predominant. We demonstrated that patients with renal impairment showed signifi- cant improvement in renal function regardless of the timing of mTOR inhibitor start, suggesting that switch to mTOR in-hibitors are required when renal function declines.
  • ||||||||||  everolimus / Generic mfg.
    Biomarker, Trial completion, Trial primary completion date, Monotherapy:  Biomarkers Predicting Successful Tacrolimus Withdrawal and Everolimus (Zortress) Monotherapy Early After Liver Transplantation (clinicaltrials.gov) -  Apr 8, 2021   
    P=N/A,  N=30, Completed, 
    We demonstrated that patients with renal impairment showed signifi- cant improvement in renal function regardless of the timing of mTOR inhibitor start, suggesting that switch to mTOR in-hibitors are required when renal function declines. Recruiting --> Completed | Trial primary completion date: May 2020 --> Mar 2021
  • ||||||||||  everolimus / Generic mfg.
    Clinical, Journal:  The mTOR-inhibitor everolimus reduces hypervolemia in patients with primary aldosteronism. (Pubmed Central) -  Apr 2, 2021   
    Recruiting --> Active, not recruiting | N=37 --> 19 | Trial primary completion date: Jan 2021 --> Jan 2022 Everolimus lowers central and peripheral blood pressure in individuals with primary aldosteronism, possibly by decreasing primary aldosteronism-induced hypervolemia and preload.
  • ||||||||||  cyclophosphamide / Generic mfg., everolimus / Generic mfg., mesna / Generic mfg.
    Enrollment open, Trial completion date, Trial primary completion date:  LITMMUS-UCSF: Liver Transplantation With Tregs at UCSF (clinicaltrials.gov) -  Apr 1, 2021   
    P1/2,  N=9, Recruiting, 
    Everolimus lowers central and peripheral blood pressure in individuals with primary aldosteronism, possibly by decreasing primary aldosteronism-induced hypervolemia and preload. Not yet recruiting --> Recruiting | Trial completion date: Apr 2027 --> Mar 2028 | Trial primary completion date: Apr 2027 --> Apr 2025
  • ||||||||||  everolimus / Generic mfg.
    Journal:  Two novel TSC2 mutations in renal epithelioid angiomyolipoma sensitive to everolimus. (Pubmed Central) -  Mar 30, 2021   
    After months of treatment with everolimus, Computer-Tomography (CT) scan results showed that everolimus successfully reduced tumor growth and distal metastasis and achieved partial response (PR) to everolimu according to Response Evaluation Criteria in Solid Tumors (RECIST version 1.1). Further Blood Routine Examination results showed the concentration of red cell mass, hemoglobin, white blood cell (WBC), platelets and hematocrit (HCT) significantly returned to normal levels indicating patients with these two TSC2 mutations could be effectively treated by everolimus.
  • ||||||||||  fulvestrant / Generic mfg.
    Journal, IO biomarker:  Practical Treatment Strategies and Future Directions After Progression While Receiving CDK4/6 Inhibition and Endocrine Therapy in Advanced HR/HER2 Breast Cancer. (Pubmed Central) -  Mar 30, 2021   
    Everolimus-based combinations and chemotherapy appear to have continued efficacy after progression while receiving CDK4/6i, although historical data on benefit include CDK4/6i-naive patients...Tumor biopsy with genomic sequencing and repeat biomarker analysis in patients with CDK4/6i- and endocrine-resistant disease will be integral to guide subsequent treatment strategies and to inform clinical trial eligibility. Promising novel therapeutics in CDK4/6i-resistant disease including oral selective estrogen down-regulators, fibroblast growth factor receptor antagonists, and immunotherapy will be discussed.
  • ||||||||||  temozolomide / Generic mfg.
    [VIRTUAL] Advanced small intestine well-differentiated neuroendocrine tumors (WD-SiNET): A survey of practice on 3rd line treatment () -  Mar 27, 2021 - Abstract #ENETS2021ENETS_265;    
    Overall, 3rd-line treatment for WD-SiNETs was: everolimus (EVE) (66.7%), PRRT (18.5%), liver embolization (LE) (7.4%) and interferon (IFN) (3.7%); chemotherapy (0%); decision was based on clinical trial data (59.3%) or personal experience (22.2%)...Chemotherapy was chosen if rapid progression (within 6 months) (WA 3.35/4), Ki-67 10-20% (WA 2.77/4), negative SSTR2 imaging (WA 2.65/4) or high tumor burden (WA 2.77/4); temozolomide or streptozocin was used with capecitabine or 5-FU (57.7%), FOLFOX (23.1%)... Selection of 3rd line therapy is based on multiple factors mainly Ki-67, rate of progression, CS and tumor burden; decisions should be made within a multidisciplinary setting.
  • ||||||||||  paclitaxel / Generic mfg.
    [VIRTUAL] TGF-β increase caspase activation and migration in typical bronchial carcinoids () -  Mar 27, 2021 - Abstract #ENETS2021ENETS_132;    
    TGF-β-increased caspase activation could explain EMT and associated malignancy features found in many TBC. Given the interplay between TGF-β and mTOR, inhibition of both pathways could represent a key solution for the therapy of these NEN, which are orphans of an effective therapeutic algorithm
  • ||||||||||  everolimus / Generic mfg.
    Journal:  Molecular Genetic Landscape of Sclerosing Pneumocytomas. (Pubmed Central) -  Mar 27, 2021   
    Our data further support that abnormal activation of the mTOR pathway is a consistent genetic event in sclerosing pneumocytoma. This warrants further exploration to determine if mTOR pathway inhibitors may be effective in patients with metastatic or recurrent disease.
  • ||||||||||  everolimus / Generic mfg.
    Journal:  Response to Everolimus of a Progressive Plexiform Neurofibroma in NF type 1. (Pubmed Central) -  Mar 26, 2021   
    In patients known to be prone to mechanistic target of rapamycin inhibitor toxicity, preemptive reduction in dose may be warranted upon initiation of cannabidiol. mTOR inhibitors may represent a treatment option to promote regression of PNs associated to NF1.
  • ||||||||||  camizestrant (AZD9833) / AstraZeneca
    New P1 trial, Combination therapy, Metastases:  AZD9833 China PK Study (clinicaltrials.gov) -  Mar 25, 2021   
    P1,  N=42, Not yet recruiting, 
  • ||||||||||  xentuzumab (BI-836845) / Boehringer Ingelheim
    Enrollment closed, Combination therapy, Metastases:  The XENERA (clinicaltrials.gov) -  Mar 23, 2021   
    P2,  N=103, Active, not recruiting, 
    The study demonstrated the safety of everolimus and lenalidomide with promising efficacy signal in thyroid and adenoid cystic cancers. Recruiting --> Active, not recruiting
  • ||||||||||  everolimus / Generic mfg.
    Journal:  Tsc1 Regulates the Proliferation Capacity of Bone-Marrow Derived Mesenchymal Stem Cells. (Pubmed Central) -  Mar 23, 2021   
    In young (28 day old) mice, Tsc1 deficiency-induced significant cell expansion of non-hematopoietic BM in vivo, and MSC colony-forming potential in vitro, that was normalized upon treatment with the mTOR inhibitor, everolimus...ShRNA-mediated knockdown of Tsc1 in BM-MSCs replicated the hyperproliferative BM-MSC phenotype and led to impaired adipogenic and myogenic differentiation. Our data show that Tsc1 is a negative regulator of BM-MSC proliferation and support a pivotal role for the Tsc1-mTOR axis in the maintenance of the mesenchymal progenitor pool.